GSK, CureVac to develop vaccine against COVID variants
Model predicts likelihood of persistent high-dose opioid use after knee surgery
3 February 2021Experiences of post-traumatic stress disorder linked to nutritional health
3 February 2021GSK, CureVac to develop vaccine against COVID variants
British pharmaceutical group GlaxoSmithKline and German biotech firm CureVac on Wednesday announced plans to jointly develop a coronavirus vaccine with the potential to counter multi-variants of COVID-19.
